Menu Close

Trending

Roche, Boehringer tap biosensor firms for patient studies
A new dawn of the genomic age: five areas set to be transformed in 2023
ABPI code updated with first social media guidance
NICE recommends first CAR-T cell therapy on NHS in England
EU clears Enhertu for HER2-low breast cancer

FreeStyle Libre

Abbott_FreeStyle_libre_3_wearable

Digital/ News/ News/ News/ Patients

Abbott makes progress with wearable for diabetic ketoacidosis

, , , , , , , , 0 Comment

Abbott is already a big player in the wearable glucose-monitoring sector, and has started working on a new

X
Abbott makes progress with wearable for diabetic ketoacidosis
https://pharmaphorum.com/news/abbott-makes-progress-with-wearable-for-diabetic-ketoacidosis/
~ai-9d6a62d3-dfc0-4e08-82a5-ed2a25f94450_

Digital/ News/ News

Real-time Abbott glucose monitor available to NHS after UK launch

, , , , , , , 0 Comment

The latest version of Abbott’s FreeStyle Libre continuous glucose monitor is now available via the NHS to eligible

X
Real-time Abbott glucose monitor available to NHS after UK launch
https://pharmaphorum.com/news/real-time-abbott-glucose-monitor-available-to-nhs-after-uk-launch/
glioblastoma

Articles/ Digital and Social Media/ Views and analysis

Digital Health Round-up – Is AI the future of cancer drug development?

, , , , , , , , 0 Comment

Does artificial intelligence hold the key to cancer drug R&D?

X
Digital Health Round-up – Is AI the future of cancer drug development?
https://pharmaphorum.com/views-and-analysis/digital-health-round-ai-future-cancer-drug-development/

Login

CONTINUE TO SITE >
X
Close in 10 seconds